Bristol Myers Squibb Company

schizophrenia, Bristol Myers Squibb

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.

Hosted on MSN · 35m

Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts

Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1%.

Business Insider · 3d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older

Bloomberg on MSN · 3d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

bovnews11h

Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Nasdaq3d

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

Bristol Myers Squibb (BMY) has been one of the most searched ... Over the past month, shares of this biopharmaceutical company have returned -0.9%, compared to the Zacks S&P 500 composite's ...

NBC Connecticut4d

Bristol Myers Squibb CEO describes new drug for treating schizophrenia

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat ...

bovnews2d

Bristol-Myers Squibb Co (BMY) Stock’s -0.01% Decrease This Year: What’s the Story?

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Seeking Alpha3d

BMY Bristol-Myers Squibb Company

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

First Hawaiian Bank Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

CSR Wire4d

Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year

Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results